However, NGS (OncomineTM Comprehensive Assay v3/Archer FusionPlex Salv GlandDx Panel) performed on the fresh tumor tissue still showed the known NTRK2 fusion, no mutation in the kinase domain, and no other alterations, particularly for genes in the mitogen-activated protein kinase pathway (Table 1). The gene discussed is NTRK2; the disease is neoplasm.